Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-β-1b treatment in relapsing remitting MS

Pharmacogenomics

Volumn 11, Issue 2, 2010, Pages 147-161

  Goertsches, Robert H ^a,b   Hecker, Michael ^b   Koczan, Dirk ^a   Serrano Fernandez, Pablo ^a   Moeller, Steffen ^a   Thiesen, Hans Juergen ^a   Zettl, Uwe K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b HANS KNÖLL INSTITUTE   (Germany)

Author keywords

Peripheral blood

Indexed keywords

CD20 ANTIGEN; INTERFERON BETA SERINE; MEMBRANE PROTEIN; PROTEIN CMPK2; PROTEIN FCER1A; PROTEIN FFAR2; RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B LYMPHOCYTE; CELL ADHESION; CLINICAL ARTICLE; CYTOLYSIS; DNA MICROARRAY; DOWN REGULATION; DRUG EFFICACY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; INNATE IMMUNITY; LYMPHOCYTE DEPLETION; MALE; MOLECULAR DYNAMICS; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION; RNA HYBRIDIZATION; TREATMENT DURATION; UPREGULATION;

COMPUTATIONAL BIOLOGY; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTERFERON-BETA; LONGITUDINAL STUDIES; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; QUALITY CONTROL; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TRANSCRIPTION, GENETIC;

EID: 77949639406     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.152     Document Type: Article

References (56)

1. Hauser SL, Oksenberg JR: The neurobiology of multiple sclerosis: genes, infammation, and neurodegeneration. Neuron 52(1), 61-76 (2006).
2. Hemmer B, Hartung HP: Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann. Neurol. 62(4), 314-326 (2007).
3. Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R; Multiple Sclerosis Therapy Consensus Group (MSTCG): Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J. Neurol. 255(10), 1449-1463 (2008).
4. Villoslada P, Steinman L, Baranzini SE: Systems biology and its application to the understanding of neurological diseases. Ann. Neurol. 65(2), 124-139 (2009).
5. Quintana FJ, Farez MF, Weiner HL: Systems biology approaches for the study of multiple sclerosis. J. Cell. Mol. Med. 12(4), 1087-1093 (2008).
6. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD: How cells respond to interferons. Annu. Rev. Biochem. 67, 227-264 (1998).
7. Der SD, Zhou A, Williams BR, Silverman RH: Identifcation of genes differentially regulated by interferon a, b, or g using oligonucleotide arrays. Proc. Natl Acad. Sci. USA 95(26), 15623-15628 (1998).
8. de Veer MJ, Holko M, Frevel M et al.: Functional classifcation of interferon-stimulated genes identifed using microarrays. J. Leukocyte Biol. 69(6), 912-920 (2001).
9. Rani MR, Shrock J, Appachi S, Rudick RA, Williams BR, Ransohoff RM: Novel interferon-b-induced gene expression in peripheral blood cells. J. Leukoc. Biol. 82(5), 1353-1360 (2007).
10. Wandinger KP, Sturzebecher CS, Bielekova B et al.: Complex immunomodulatory effects of interferon-b in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol. 50(3), 349-357 (2001).
11. Koike F, Satoh J, Miyake S et al.: Microarray ana lysis identifes interferon b-regulated genes in multiple sclerosis. J. Neuroimmunol. 139(1-2), 109-118 (2003).
12. Sturzebecher S, Wandinger KP, Rosenwald A et al.: Expression profling identifes responder and non-responder phenotypes to interferon-b in multiple sclerosis. Brain 126(6), 1419-1429 (2003).
13. Weinstock-Guttman B, Badgett D, Patrick K et al.: Genomic effects of IFN-b in multiple sclerosis patients. J. Immunol. 171(5), 2694-2702 (2003).
14. Achiron A, Gurevich M, Magalashvili D, Kishner I, Dolev M, Mandel M: Understanding autoimmune mechanisms in multiple sclerosis using gene expression microarrays: treatment effect and cytokine-related pathways. Clin. Dev. Immunol. 11(3-4), 299-305 (2004).
15. Iglesias AH, Camelo S, Hwang D, Villanueva R, Stephanopoulos G, Dangond F: Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J. Neuroimmunol. 150(1-2), 163-177 (2004).
16. Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ: Gene expression profling of relevant biomarkers for treatment evaluation in multiple sclerosis. J. Neuroimmunol. 152(1-2), 126-139 (2004).
17. Baranzini SE, Mousavi P, Rio J et al.: Transcription-based prediction of response to IFNb using supervised computational methods. PLoS Biol. 3(1), E2 (2005).
18. Satoh J, Nakanishi M, Koike F et al.: T cell gene expression profling identifes distinct subgroups of Japanese multiple sclerosis patients. J. Neuroimmunol. 174(1-2), 108-118 (2006).
19. Satoh J, Nanri Y, Tabunoki H, Yamamura T: Microarray ana lysis identifes a set of CXCR3 and CCR2 ligand chemokines as early IFNb-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNb-related adverse effects in multiple sclerosis. BMC Neurol. 19, 6-18 (2006).
20. Palacios R, Goni J, Martinez-Forero I et al.: A network ana lysis of the human T-cell activation gene network identifes JAGGED1 as a therapeutic target for autoimmune diseases. PLoS ONE 2(11), E1222 (2007).
21. Annibali V, Di Giavanni S, Cannoni S et al.: Gene expression profles reveal homeostatic dynamics during interferon-b therapy in multiple sclerosis. Autoimmunity 40(1), 16-22 (2007).
22. Singh MK, Scott TF, La Framboise WA, Hu FZ, Post JC, Ehrlich GD: Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing b-interferon therapy. J. Neurol. Sci. 258(1-2), 52-59 (2007).
23. Fernald GH, Knott S, Pachner A et al.: Genome-wide network ana lysis reveals the global properties of IFN-b immediate transcriptional effects in humans. J. Immunol. 178(8), 5076-5085 (2007).
24. Reder AT, Velichko S, Yamaguchi KD et al.: IFN-b1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J. Interferon Cytokine Res. 28(5), 317-331 (2008).
25. Hilpert J, Beekman JM, Schwenke S et al.: Biological response genes after single dose administration of interferon b-1b to healthy male volunteers. J. Neuroimmunol. 199(1-2), 115-125 (2008).
26. Weinstock-Guttman B, Bhasi K, Badgett D et al.: Genomic effects of once-weekly, intramuscular interferon-b1a treatment after the frst dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients. J. Neuroimmunol. 205(1-2), 113-125 (2008).
27. Goertsches RH, Hecker M, Zettl UK: Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networks. J. Neurol. 225 (Suppl. 6), 48-57 (2008).
28. Borden EC, Sen GC, Uze G et al.: Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 6(12), 975-990 (2007).
29. van Baarsen LGM, Vosslamber S, Tijssen M et al.: Pharmacogenomics of interferon-b therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 3(4), E1927 (2008).
30. Satoh J, Illes Z, Peterfalvi A, Tabunoki H, Rozsa C, Yamamura T: Aberrant transcriptional regulatory network in T cells of multiple sclerosis. Neurosci. Lett. 422(1), 30-33 (2007).
31. Gneiss C, Tripp P, Reichartseder F et al.: Differing immunogenic potentials of interferon b preparations in multiple sclerosis patients. Mult. Scler. 12(6), 731-737 (2006).
32. McDonald WI, Compston A, Edan G et al.: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 50(1), 121-127 (2001).
33. Yang IV, Chen E, Hasseman JP et al.: Within the fold: assessing differential expression measures and reproducibility in microarray assays. Genome Biol. 3(11), research0062 (2002).
34. Hecker M, Goertsches RH, Engelmann R, Thiesen HJ, Guthke R: Integrative modelling of transcriptional regulation in response to antirheumatic therapy. BMC Bioinformatics 10(1), 262 (2009).
35. Pepper SD, Saunders EK, Edwards LE, Wilson CL, Miller CJ: The utility of MAS5 expression summary and detection call algorithms. BMC Bioinformatics 30(8), 273 (2007).
36. Ferrari F, Bortoluzzi S, Coppe A et al.: Novel defnition fles for human GeneChips based on GeneAnnot. BMC Bioinformatics 15(8), 446 (2007).
37. Chalifa-Caspi V, Yanai I, Ophir R et al.: GeneAnnot: comprehensive two-way linking between oligonucleotide array probesets and GeneCards genes. Bioinformatics 20(9), 1457-1458 (2004).
38. Ashburner M, Ball CA, Blake JA et al.; The Gene Ontology Consortium: Gene Ontology: tool for the unifcation of biology. Nat. Genet. 25(1), 25-29 (2000).
39. Falcon S, Gentleman R: Using GOstats to test gene lists for GO term association. Bioinformatics 23(2), 257-258 (2007).
40. Shannon P, Markiel A, Ozier O et al.: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13(11), 2498-2504 (2003).
41. Gilli F, Marnetto F, Caldano M et al.: Biological responsiveness to frst injections of interferon-b in patients with multiple sclerosis. J. Neuroimmunol. 158(1-2), 195-203 (2005).
42. Brown AJ, Jupe S, Briscoe CP: A family of fatty acid binding receptors. DNA Cell Biol. 24(1), 54-61 (2005).
43. Hirasawa A, Hara T, Katsuma S, Adachi T, Tsujimoto G: Free fatty acid receptors and drug discovery. Biol. Pharm. Bull. 31(10), 1847-1851 (2008).
44. Hemmi H, Kaisho T, Takeuchi O et al.: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3(2), 196-200 (2002).
45. O'Neill LA: Targeting signal transduction as a strategy to treat infammatory diseases. Nat. Rev. Drug Discov. 5(7), 549-563 (2006).
46. Schulthess FT, Paroni F, Sauter NS et al.: CXCL10 impairs b cell function and viability in diabetes through TLR4 signaling. Cell Metab. 9(2), 125-139 (2009).
47. Krumbholz M, Faber H, Steinmeyer F et al.: Interferon-b increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131(6), 1455-1463 (2008).
48. Gilli F, Marnetto F, Caldano M et al.: Biological markers of interferon-b therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult. Scler. 12(1), 47-57 (2006)
49. Hesse D, Sellebjerg F, Sorensen PS: Absence of MxA induction by interferon b in patients with MS refects complete loss of bioactivity. Neurology 73(5), 372-377 (2009).
50. Sellebjerg F, Krakauer M, Hesse D et al.: Identifcation of new sensitive biomarkers for the in vivo response to interferon-b treatment in multiple sclerosis using DNA-array evaluation. Eur. J. Neurol. (2009) (Epub ahead of print).
51. Comabella M, Lünemann JD, Río J et al.: A type I interferon signature in monocytes is associated with poor response to interferon-b in multiple sclerosis. Brain 2(Pt 12), 3353-3365 (2009).
52. O'Doherty C, Villoslada P, Vandenbroeck K: Pharmacogenomics of Type I interferon therapy: a survey of response-modifying genes. Cytokine Growth Factor Rev. 18(3-4), 211-222 (2007).
53. Vandenbroeck K, Matute C: Pharmacogenomics of the response to IFN-b in multiple sclerosis: ramifcations from the frst genome-wide screen. Pharmacogenomics 9(5), 639-645 (2008).
54. Hwang D, Rust AG, Ramsey S et al.: A data integration methodology for systems biology. Proc. Natl Acad. Sci. USA 102(48), 17296-17301 (2005).
55. Bauch A, Superti-Furga G: Charting protein complexes, signaling pathways, and networks in the immune system. Immunol. Rev. 210, 187-207 (2006).
56. Lamb J, Crawford ED, Peck D et al.: The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313(5795), 1929-1935 (2006).